The Breo Ellipta lawsuit has attracted attention from patients, healthcare consumers, and people researching potential legal claims involving prescription medications. However, understanding the legal situation requires distinguishing between patent infringement litigation involving the drug’s manufacturer and allegations concerning medication-related injuries.
Breo Ellipta is a prescription inhaler manufactured by GlaxoSmithKline (GSK). It combines two active ingredients, fluticasone furoate and vilanterol, and is prescribed for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Although the medication provides important respiratory benefits, its prescribing information identifies several potential health risks, including pneumonia in certain COPD patients and cardiovascular effects.
One of the significant legal developments involves GSK’s patent infringement dispute with Transpire Bio, a company seeking to introduce a generic version of Breo Ellipta. The dispute concerns intellectual property rights rather than compensation for patients who experienced side effects.
As of November 2026, publicly available court records and company disclosures identify this patent litigation, but they do not establish a nationwide Breo Ellipta personal injury settlement or a certified patient injury class action.
This article examines the known legal proceedings, medication safety information, potential injury-related concerns, and what patients should understand before considering legal action.
What Is the Breo Ellipta Lawsuit About?
The term “Breo Ellipta lawsuit” can refer to different legal disputes involving the medication and its manufacturer. It is important not to confuse intellectual property litigation with potential product liability claims.
The most clearly documented ongoing dispute involves GlaxoSmithKline and Transpire Bio.
In September 2025, GSK filed a lawsuit against Transpire Bio in the U.S. District Court for the Southern District of Florida. GSK alleged that Transpire’s proposed generic version of Breo Ellipta infringed its patents and trade dress.
The dispute arose after GSK received a Paragraph IV certification notice from Transpire in August 2025. Such notices are part of the regulatory process through which generic drug manufacturers challenge patents listed for brand-name medications.
GSK’s lawsuit seeks to protect its intellectual property rights against the proposed generic product.
This is not a patient injury class action. The case does not establish that Breo Ellipta caused injuries, that GSK owes patients compensation, or that a settlement fund is available to consumers.
Separately, patients may have questions about whether certain adverse effects could support an individual product liability claim. Those questions depend on the medical evidence, applicable state laws, and the specific circumstances of each case.
What Is Breo Ellipta and Who Makes It?
Breo Ellipta is a prescription inhalation medication developed and marketed by GlaxoSmithKline (GSK).
It contains two active ingredients:
- Fluticasone furoate: An inhaled corticosteroid that helps reduce inflammation in the airways.
- Vilanterol: A long-acting beta2-adrenergic agonist (LABA) that helps relax airway muscles and improve airflow.
The medication is designed for once-daily maintenance treatment. In the United States, it is approved for certain adults with asthma and patients with COPD.
Breo Ellipta is not intended to provide immediate relief during sudden breathing difficulties or acute bronchospasm. Patients may require a separate rescue medication for those situations.
The medication received its initial U.S. approval in 2013.
Its manufacturer, GSK, is a global pharmaceutical company involved in developing and marketing prescription medicines and vaccines.
GSK vs. Transpire Bio: The Breo Ellipta Patent Infringement Case
One of the most important developments in the Breo Ellipta legal history is the patent dispute between GSK and Transpire Bio.
How Did the Dispute Begin?
In August 2025, GSK received a Paragraph IV certification notice from Transpire Bio concerning its proposed generic version of Breo Ellipta.
Under the Hatch-Waxman Act, generic manufacturers can submit applications seeking approval for generic versions of brand-name drugs. A Paragraph IV certification challenges one or more patents listed for the original medication.
After receiving the notice, GSK filed a lawsuit on September 25, 2025, in the U.S. District Court for the Southern District of Florida.
The case is identified as:
- Case name: Glaxo Group Limited et al. v. Transpire Bio Inc.
- Case number: 0:2025cv61939
- Court: U.S. District Court for the Southern District of Florida
- Filing date: September 25, 2025
- Nature of dispute: Patent and intellectual property infringement
GSK alleged that Transpire’s proposed generic inhaler infringed its patents and trade dress.
These are allegations made by the plaintiffs and should not be treated as final judicial findings.
What Is the Current Status of the Case?
The litigation continued through 2026.
GSK’s corporate disclosures initially identified November 2, 2026, as the scheduled trial date. However, an amended scheduling order issued on April 8, 2026, moved the trial to September 20, 2027.
Court records also show continuing discovery-related proceedings during October 2026.
As of November 2026, the dispute remains an intellectual property case between pharmaceutical companies. It is not a settlement proceeding for patients who used Breo Ellipta.
The outcome could affect the timing and availability of a proposed generic version of the medication, depending on the court’s eventual decisions and other regulatory requirements.
Why Does This Lawsuit Matter?
The dispute matters because generic competition can influence medication availability and pricing.
If a generic version receives regulatory approval and can legally enter the market, patients and healthcare providers may have additional treatment options.
However, a patent lawsuit does not automatically determine whether a medication is medically safe, whether it caused a particular patient’s injury, or whether its manufacturer is liable for damages.
Breo Ellipta Side Effects and FDA Safety Warnings
Although Breo Ellipta is an approved prescription medication, its official prescribing information identifies several potential adverse reactions and safety concerns.
The FDA-approved labeling provides important information about the risks healthcare professionals should consider when prescribing the medication.
1. Pneumonia Risk
One of the significant warnings associated with Breo Ellipta concerns pneumonia in patients with COPD.
The prescribing information states that an increased incidence of pneumonia was observed among COPD patients receiving Breo Ellipta in clinical trials.
In certain clinical studies, pneumonia cases resulted in hospitalization, and some were fatal.
The labeling advises healthcare professionals to monitor patients for possible pneumonia because its symptoms can overlap with COPD exacerbations.
This warning is particularly relevant when evaluating claims involving patients who developed pneumonia after using the medication.
However, the existence of a warning does not establish that Breo Ellipta caused pneumonia in every patient who developed the condition.
2. Cardiovascular Effects
Breo Ellipta contains vilanterol, a long-acting beta2-adrenergic agonist.
According to its prescribing information, medications containing beta2-agonists may produce cardiovascular effects in certain patients.
Reported effects can include:
- Increased heart rate.
- Changes in blood pressure.
- Cardiac arrhythmias.
- Supraventricular tachycardia.
- Other changes in cardiovascular function.
The labeling recommends caution when prescribing Breo Ellipta to patients with cardiovascular disorders.
These warnings are important for patients with pre-existing heart conditions or individuals who experience unusual cardiovascular symptoms while using the medication.
3. Oral Thrush and Fungal Infections
Breo Ellipta contains an inhaled corticosteroid, which can increase the possibility of localized fungal infections in the mouth and throat.
One potential condition is oropharyngeal candidiasis, commonly known as oral thrush.
Symptoms may include:
- White patches inside the mouth.
- Soreness or irritation.
- Difficulty swallowing.
- Redness in the mouth or throat.
The prescribing information recommends rinsing the mouth with water after using the inhaler and spitting the water out rather than swallowing it.
4. Adrenal Suppression
Long-term corticosteroid exposure can affect the body’s natural production of certain hormones.
The prescribing information warns that hypercorticism and adrenal suppression may occur in susceptible individuals or with excessive corticosteroid exposure.
Patients transitioning from systemic corticosteroid treatment also require careful medical supervision.
5. Bone Mineral Density Reduction
The prescribing information identifies a potential reduction in bone mineral density associated with inhaled corticosteroid use.
This may be relevant for patients with existing osteoporosis risk factors or those receiving long-term corticosteroid treatment.
Healthcare professionals may consider evaluating bone mineral density in patients who have additional risk factors.
6. Glaucoma and Cataracts
Long-term administration of inhaled corticosteroids has also been associated with reports of glaucoma, increased intraocular pressure, and cataracts.
Patients who experience changes in vision or have a history of eye-related conditions may require additional monitoring.
Important Medication Safety Note
The presence of a listed side effect does not mean every patient will experience it or that the medication is necessarily responsible for an individual medical condition.
Patients should discuss concerns with their healthcare professionals and should not discontinue prescribed Breo Ellipta without medical guidance.
Are Patients Filing Breo Ellipta Injury Lawsuits?
Patients who experience serious medical complications while using prescription medications may have questions about whether they can pursue compensation.
In general, pharmaceutical product liability lawsuits can involve allegations that a manufacturer:
- Failed to provide adequate warnings about known medication risks.
- Misrepresented the safety or effectiveness of a prescription drug.
- Manufactured a defective product.
- Failed to comply with applicable legal or regulatory requirements.
In a potential Breo Ellipta injury claim, a patient would generally need to establish the relevant legal elements under the applicable state law.
These may include evidence of exposure to the medication, a qualifying injury, causation, and legally actionable conduct by the manufacturer.
However, it is important to distinguish potential legal theories from actual filed cases.
As of November 2026, the publicly verified Breo Ellipta proceedings discussed in this article primarily concern patent infringement and generic competition.
The available court records reviewed for this article do not establish a nationwide coordinated personal injury litigation program, a certified patient injury class, or a confirmed settlement for Breo Ellipta users.
Patients should therefore be cautious about websites or advertisements suggesting that an approved injury settlement is already available.
Is There a Breo Ellipta Class Action Settlement?
There is no verified nationwide Breo Ellipta patient injury class action settlement established by the court records and official disclosures reviewed for this article.
This distinction is important because several different types of legal disputes can involve the same medication.
A patent infringement settlement between pharmaceutical companies would not automatically create a compensation fund for patients.
Similarly, a lawsuit filed by an individual patient would not automatically mean that all other Breo Ellipta users qualify for compensation.
Before believing claims about a settlement, readers should look for:
- An actual court-approved settlement agreement.
- A court order granting preliminary or final approval, where applicable.
- The name of an appointed settlement administrator.
- Official eligibility requirements.
- A verified claims submission deadline.
- Information explaining how compensation will be calculated.
At present, no verified nationwide Breo Ellipta patient settlement fund or official patient claim portal has been established in the sources reviewed.
What About the $89.7 Million Breo Ellipta Patent Verdict?
Readers may encounter references to an $89.7 million verdict connected to Breo Ellipta.
That figure relates to a separate intellectual property dispute involving Vectura and GSK.
It concerns patent rights associated with inhaler technology, not compensation awarded to patients for medication-related injuries.
The Vectura litigation should not be confused with the ongoing GSK–Transpire Bio dispute or potential individual product liability claims.
Patients should not assume they are entitled to a portion of that patent-related award.
Breo Ellipta Lawsuit Eligibility: What Patients Should Know
Because no verified nationwide patient injury settlement has been established, there are currently no official settlement eligibility requirements for Breo Ellipta users.
Nevertheless, individuals who believe they suffered a serious injury associated with the medication may wish to understand the factors an attorney could examine.
1. Documented Breo Ellipta Use
Medical records, pharmacy receipts, prescription histories, and healthcare provider documentation may help establish whether someone used the medication.
The duration of use, prescribed dosage, and treatment history may also be relevant.
2. A Diagnosed Medical Condition
An individual considering a potential claim would generally need medical documentation of the injury.
Depending on the circumstances, relevant conditions could include pneumonia, cardiovascular complications, or other medical problems identified in the medication’s safety information.
Simply experiencing a common side effect does not automatically establish a valid product liability claim.
3. Medical Evidence Connecting the Medication to the Injury
Establishing a connection between a prescription medication and a medical condition can be complicated.
A healthcare professional may need to consider:
- When the medication was started.
- When the symptoms appeared.
- Whether the patient had pre-existing conditions.
- Whether other medications could have contributed.
- Whether alternative explanations exist.
- Whether the available scientific evidence supports causation.
The fact that an injury occurred after taking Breo Ellipta does not, by itself, prove that the medication caused it.
4. Evidence of Manufacturer Liability
Depending on the legal theory, an attorney may review the medication’s labeling, safety communications, clinical evidence, marketing materials, and the manufacturer’s knowledge of relevant risks.
The applicable legal requirements differ between jurisdictions.
5. Filing Within the Applicable Legal Deadline
Product liability claims are subject to statutes of limitations.
These deadlines vary depending on the state, the type of claim, and when the injury was discovered or reasonably should have been discovered.
Anyone considering legal action should seek advice promptly rather than waiting for a possible nationwide settlement announcement.
Can You Receive Compensation for Breo Ellipta Injuries?
Whether an individual can recover compensation depends on the facts of the case and whether the legal requirements for a product liability claim can be established.
Potential categories of damages in a successful pharmaceutical injury lawsuit may include:
- Medical expenses.
- Future healthcare costs.
- Lost wages.
- Reduced earning capacity.
- Physical pain and suffering.
- Other legally recognized losses.
The availability and calculation of damages depend on the applicable law and supporting evidence.
There is no verified Breo Ellipta patient settlement amount or established per-person payout as of November 2026.
Any website advertising guaranteed compensation or specific payout figures without an actual settlement agreement should be treated cautiously.
Patients should also understand that compensation is not automatic merely because a medication’s prescribing information lists a particular adverse reaction.
How to Report a Breo Ellipta Side Effect
Patients who believe they have experienced an adverse reaction can report it through the FDA’s MedWatch program.
The FDA uses adverse-event reports to monitor potential medication safety concerns.
However, an adverse-event report does not independently establish that a particular drug caused the reported condition.
Patients can also contact GlaxoSmithKline through the contact information provided in the medication’s prescribing information.
For serious or worsening symptoms, patients should seek appropriate medical attention rather than relying solely on an adverse-event reporting system.
Frequently Asked Questions About the Breo Ellipta Lawsuit
1. Is there a Breo Ellipta lawsuit in 2026?
Yes. GSK is involved in a patent infringement lawsuit against Transpire Bio concerning its proposed generic version of Breo Ellipta. However, this is a commercial intellectual property dispute, not a confirmed nationwide patient injury class action.
govinfo.gov+1
2. Is there a Breo Ellipta class action lawsuit?
No verified nationwide Breo Ellipta patient injury class action has been established in the court records reviewed for this article. The existing patent litigation should not be confused with a patient compensation lawsuit.
3. Is there a Breo Ellipta settlement in 2026?
There is no verified nationwide patient injury settlement or official claims program established as of November 2026. Patients should be cautious about websites advertising settlement payouts without supporting court documents.
4. What is the main legal dispute involving Breo Ellipta?
The main documented ongoing dispute involves GSK and Transpire Bio. GSK alleges that Transpire’s proposed generic inhaler infringes its patents and trade dress. The trial was rescheduled to September 20, 2027.
Additional information+1
5. What are the potential side effects of Breo Ellipta?
Potential side effects and safety concerns include pneumonia in COPD patients, oral thrush, cardiovascular effects, adrenal suppression, reduced bone mineral density, and eye-related complications. The risks vary between individuals.
dailymed.nlm.nih.gov+1
6. Can I sue GSK for injuries caused by Breo Ellipta?
An individual may wish to consult a product liability attorney if they believe Breo Ellipta caused a serious injury. However, a potential claim would require evidence supporting the injury, causation, and manufacturer liability under applicable law. There is no automatic right to compensation simply because a patient experienced a listed side effect.
7. Has Breo Ellipta been recalled?
The sources reviewed for this article do not establish a nationwide recall of Breo Ellipta. Patients should check the FDA’s current recall and safety information for any subsequent developments.
8. What is the $89.7 million Breo Ellipta lawsuit?
The widely reported $89.7 million figure relates to a separate patent dispute involving Vectura and GSK over inhaler technology. It is not a patient injury settlement and does not represent compensation available to Breo Ellipta users.
9. What should I do if I experience serious side effects?
Contact your healthcare professional promptly. Seek urgent medical attention for serious or worsening symptoms. You can also report suspected adverse reactions through the FDA’s MedWatch program. Do not stop prescribed treatment without discussing it with your healthcare provider.
Final Thoughts
The Breo Ellipta lawsuit highlights the importance of understanding the difference between pharmaceutical patent disputes and patient injury litigation.
The most clearly documented ongoing legal proceeding involves GlaxoSmithKline and Transpire Bio over the proposed generic version of Breo Ellipta. The dispute concerns intellectual property rights, with a trial currently scheduled for September 2027.
Separately, Breo Ellipta’s prescribing information identifies potential health risks, including pneumonia in COPD patients and cardiovascular effects. These warnings are important for patients and healthcare professionals, but they do not independently establish manufacturer liability.
As of November 2026, there is no verified nationwide Breo Ellipta patient injury settlement, confirmed compensation fund, or established patient claim portal.
Readers should rely on official court records, FDA safety information, and verified company disclosures when following developments. Anyone who believes they have suffered a medication-related injury should consult a qualified attorney to understand their individual legal options.
Article Disclaimer
This article is for informational and educational purposes only and does not constitute legal, medical, or financial advice. The information presented reflects publicly available sources reviewed as of November 9, 2026. Lawsuits, regulatory developments, and medication safety information may change. Readers should consult qualified legal professionals regarding individual claims and healthcare providers regarding medication-related concerns. The Legal Briefs does not guarantee eligibility for compensation or any particular legal outcome.

